JW (Cayman) Therapeutics Co. Ltd (JNY.F)
| Previous Close | 0.2440 |
| Open | 0.2560 |
| Bid | 0.2600 x N/A |
| Ask | 0.2880 x N/A |
| Day's Range | 0.2540 - 0.2620 |
| 52 Week Range | 0.1800 - 0.3295 |
| Volume | |
| Avg. Volume | 11 |
| Market Cap | 113.516M |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings Date | Mar 20, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswirePreliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress
JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel ("relma-cel") injection in adults with active systemic lupus erythematosus ("SLE") in China at the 2024 European Alliance of Associations for Rheumatology Congress ("EULAR 2024"
PR NewswireJW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed o
PR NewswireJW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development and commercialization of a chimeric antigen receptor (CAR) T-cell therapy product for autoimmune diseases (AID program) in Greater China.
